1
|
Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J
and Liu M: Long inter-genic noncoding RNA HOTAIR is overexpressed
and regulates PTEN methylation in laryngeal squamous cell
carcinoma. Am J Pathol. 182:64–70. 2013. View Article : Google Scholar
|
2
|
Bingol F, Yoruk O, Bingol BO, Erdemci B,
Ozkan O and Mazlumoglu MR: Estimation of the efficacy of
chemo-radiotherapy on tumor regression in the patients with
laryngeal cancer via computerized tomography using the Cavalieri
method. Acta Otolaryngol. 136:164–167. 2016. View Article : Google Scholar
|
3
|
Halec G, Holzinger D, Schmitt M,
Flechtenmacher C, Dyckhoff G, Lloveras B, Höfler D, Bosch FX and
Pawlita M: Biological evidence for a causal role of HPV16 in a
small fraction of laryngeal squamous cell carcinoma. Br J Cancer.
109:172–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yu GP, Mehta V, Branovan D, Huang Q,
Hashibe M, Zhang ZF and Schantz SP: Improved survival among
patients with base of tongue and tonsil cancer in the United
States. Cancer Causes Control. 23:153–164. 2012. View Article : Google Scholar
|
5
|
Shen Z, Li Q, Deng H, Lu D, Song H and Guo
J: Long non-coding RNA profiling in laryngeal squamous cell
carcinoma and its clinical significance: Potential biomarkers for
LSCC. PLoS One. 9:e1082372014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Amend SR and Pienta KJ: Ecology meets
cancer biology: The cancer swamp promotes the lethal cancer
phenotype. Oncotarget. 6:9669–9678. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Marumoto T, Zhang D and Saya H: Aurora-A -
a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Rojanala S, Han H, Muñoz RM, Browne W,
Nagle R, Von Hoff DD and Bearss DJ: The mitotic serine threonine
kinase, Aurora-2, is a potential target for drug development in
human pancreatic cancer. Mol Cancer Ther. 3:451–457.
2004.PubMed/NCBI
|
10
|
Watanabe T, Imoto I, Katahira T, Hirasawa
A, Ishiwata I, Emi M, Takayama M, Sato A and Inazawa J:
Differentially regulated genes as putative targets of
amplifications at 20q in ovarian cancers. Jpn J Cancer Res.
93:1114–1122. 2002. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bischoff JR, Anderson L, Zhu Y, Mossie K,
Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et
al: A homologue of Drosophila aurora kinase is oncogenic and
amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Xing Z, Gao S, Duan Y, Han H, Li L, Yang Y
and Li Q: Delivery of DNAzyme targeting aurora kinase A to inhibit
the proliferation and migration of human prostate cancer. Int J
Nanomedicine. 10:5715–5727. 2015.PubMed/NCBI
|
13
|
Zhang H, Chen X, Jin Y, Liu B and Zhou L:
Overexpression of Aurora-A promotes laryngeal cancer progression by
enhancing invasive ability and chromosomal instability. Eur Arch
Otorhinolaryngol. 269:607–614. 2012. View Article : Google Scholar :
|
14
|
Zhang H, Chen X, Liu B and Zhou L: Effects
of stable knockdown of Aurora kinase A on proliferation, migration,
chromosomal instability, and expression of focal adhesion kinase
and matrix metalloproteinase-2 in HEp-2 cells. Mol Cell Biochem.
357:95–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Rao Q, Chen Y, Yeh CR, Ding J, Li L, Chang
C and Yeh S: Recruited mast cells in the tumor microenvironment
enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2
EMT/MMP9 signals. Oncotarget. 7:7842–7855. 2016.
|
16
|
Qin Y, Tang B, Hu CJ, Xiao YF, Xie R, Yong
X, Wu YY, Dong H and Yang SM: An hTERT/ZEB1 complex directly
regulates E-cadherin to promote epithelial-to-mesenchymal
transition (EMT) in colorectal cancer. Oncotarget. 7:351–631.
2016.
|
17
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Burnett JP, Korkaya H, Ouzounova MD, Jiang
H, Conley SJ, Newman BW, Sun L, Connarn JN, Chen CS, Zhang N, et
al: Trastuzumab resistance induces EMT to transform
HER2+ PTEN− to a triple negative breast
cancer that requires unique treatment options. Sci Rep.
5:158212015. View Article : Google Scholar
|
19
|
Attramadal CG, Kumar S, Boysen ME, Dhakal
HP, Nesland JM and Bryne M: Tumor budding, EMT and cancer stem
cells in T1-2/N0 oral squamous cell carcinomas. Anticancer Res.
35:6111–6120. 2015.PubMed/NCBI
|
20
|
Wang SC, Chai DS, Chen CB, Wang ZY and
Wang L: HPIP promotes thyroid cancer cell growth, migration and EMT
through activating PI3K/AKT signaling pathway. Biomed Pharmacother.
75:33–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Buczek ME, Miles AK, Green W, Johnson C,
Boocock DJ, Pockley AG, Rees RC, Hulman G, van Schalkwyk G,
Parkinson R, et al: Cytoplasmic PML promotes TGF-β-associated
epithelial-mesenchymal transition and invasion in prostate cancer.
Oncogene. 43:124–127. 2015.
|
22
|
Ota I, Masui T, Kurihara M, Yook JI,
Mikami S, Kimura T, Shimada K, Konishi N, Yane K, Yamanaka T, et
al: Snail-induced EMT promotes cancer stem cell-like properties in
head and neck cancer cells. Oncol Rep. 35:261–266. 2016.
|
23
|
Broster SA and Kyprianou N:
Epithelial-mesenchymal transition in prostatic disease. Future
Oncol. 11:3197–3206. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Lee SC, Kim OH, Lee SK and Kim SJ: IWR-1
inhibits epithelial-mesenchymal transition of colorectal cancer
cells through suppressing Wnt/β-catenin signaling as well as
survivin expression. Oncotarget. 6:27146–27159. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
D'Assoro AB, Liu T, Quatraro C, Amato A,
Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, et
al: The mitotic kinase Aurora-A promotes distant metastases by
inducing epithelial-to-mesenchymal transition in ERα+
breast cancer cells. Oncogene. 33:599–610. 2014. View Article : Google Scholar
|
28
|
Guan Z, Wang XR, Zhu XF, Huang XF, Xu J,
Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, et al: Aurora-A, a
negative prognostic marker, increases migration and decreases
radiosensitivity in cancer cells. Cancer Res. 67:10436–10444. 2007.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Thiyagarajan V, Tsai MJ and Weng CF:
Antroquinonol targets FAK-signaling pathway suppressed cell
migration, invasion, and tumor growth of C6 glioma. PLoS One.
10:e01412852015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Sun L, Liu L, Liu X, Wang Y, Li M, Yao L,
Yang J, Ji G, Guo C, Pan Y, et al: MGr1-Ag/37LRP induces cell
adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway
in gastric cancer. Cancer Sci. 105:651–659. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lin Y, Rao J, Zha XL and Xu H:
Angiopoietin-like 3 induces podocyte F-actin rearrangement through
integrin αV/β3/FAK/PI3K pathway-mediated Rac1
activation. Biomed Res Int. 2013:1356082013.
|
32
|
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong
SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes
cell glycolysis, growth, migration, and invasion in non-small cell
lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Hochwald SN, Nyberg C, Zheng M, Zheng D,
Wood C, Massoll NA, Magis A, Ostrov D, Cance WG and Golubovskaya
VM: A novel small molecule inhibitor of FAK decreases growth of
human pancreatic cancer. Cell Cycle. 8:2435–2443. 2009. View Article : Google Scholar : PubMed/NCBI
|
34
|
Greger JG, Eastman SD, Zhang V, Bleam MR,
Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L and
Gilmer TM: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors
overcome acquired resistance to the BRAF inhibitor GSK2118436
dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther.
11:909–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Evans EB and Lin SY: New insights into
tumor dormancy: Targeting DNA repair pathways. World J Clin Oncol.
6:80–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH,
He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, et al: Pro-apoptotic and
pro-autophagic effects of the Aurora kinase A inhibitor alisertib
(MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the
activation of mitochondria-mediated pathway and inhibition of p38
MAPK/PI3K/Akt/mTOR signaling pathway. Drug Des Devel Ther.
9:1555–1584. 2015.PubMed/NCBI
|
37
|
Dar AA, Goff LW, Majid S, Berlin J and
El-Rifai W: Aurora kinase inhibitors - rising stars in cancer
therapeutics? Mol Cancer Ther. 9:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
38
|
Gu K, Li MM, Shen J, Liu F, Cao JY, Jin S
and Yu Y: Interleukin-17-induced EMT promotes lung cancer cell
migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer
Res. 5:1169–1179. 2015.
|